AXSM
NASDAQ
US
Axsome Therapeutics, Inc. - Common Stock
$168.51
▼ $-3.28
(-1.91%)
Vol 617K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$9.2B
ROE
-356.4%
Margin
-40.8%
D/E
263.51
Beta
0.42
52W
$76–$159
Wall Street Consensus
26 analysts · Apr 20269
Strong Buy
15
Buy
2
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
RPRX
Royalty Pharma PLC
P/E 29.2
$22.3B
VTRS
Viatris Inc
$14.3B
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34.5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76.6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
About Axsome Therapeutics, Inc. - Common Stock
Axsome Therapeutics (AXSM) — біофармацевтична компанія, що розробляє та комерціалізує нові методи лікування розладів центральної нервової системи (ЦНС). Їхній основний продукт, Auvelity, є першим і єдиним пероральним препаратом з новим механізмом дії для лікування великого депресивного розладу (ВДР). Компанія має перспективний портфель кандидатів на ліки, орієнтованих на значні незадоволені потреби в неврології.
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.68 | $-0.56 | +$0.12 |
| Sep 2025 | $-0.88 | $-0.94 | $-0.06 |
| Jun 2025 | $-1.12 | $-0.97 | +$0.15 |
| Mar 2025 | $-1.35 | $-1.22 | +$0.13 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | $118.8M | $121.5M | $150.0M | $171.0M | $196.0M |
| Net Income | -$74.9M | -$59.4M | -$48.0M | -$47.2M | -$28.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -358.0% | -357.6% | -357.6% | -357.6% | -357.2% | -356.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -32.0% | -49.9% | -49.9% | -49.9% | -40.9% | -40.8% |
| Gross Margin | 91.0% | 91.5% | 91.5% | 91.5% | 91.9% | 91.9% |
| D/E Ratio | 264.38 | 264.59 | 264.59 | 264.59 | 264.24 | 263.51 |
| Current Ratio | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
Key Ratios
ROA (TTM)
-37.0%
P/S (TTM)
16.40
P/B
71.9
EPS (TTM)
$-4.65
CF/Share
$-4.39
52W High
$158.56
52W Low
$75.56
$75.56
52-Week Range
$158.56
Financial Health
Free Cash Flow
-$18.7M
Net Debt
-$104.8M
Cash
$322.9M
Total Debt
$218.1M
As of Dec 31, 2025
How does AXSM compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
AXSM valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
16.4
▲
144%
above
peers
(6.7)
vs Peers
vs Industry
Pricier
P/B ratio
71.9
▲
1278%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
AXSM profitability vs Pharmaceuticals peers
ROE
-356.4%
▼
1267%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
-40.8%
▼
2714%
below
peers
(-1.5%)
vs Peers
vs Industry
Weak
Gross margin
91.9%
▲
3%
above
peers
(88.9%)
vs Peers
vs Industry
In line
ROA
-37.0%
▼
292%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
AXSM financial health vs Pharmaceuticals peers
D/E ratio
263.5
▲
863%
above
peers
(27.4)
vs Peers
vs Industry
High debt
Current ratio
1.6
▼
55%
below
peers
(3.5)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
29%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
AXSM fundamentals radar
AXSM
Peer median
Industry
AXSM profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AXSM vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
JACOBSON MARK L
Chief Operating Officer · Feb 26
35378 shs
COLEMAN MARK H
Director · Feb 26
25000 shs
JACOBSON MARK L
Chief Operating Officer · Feb 26
35378 shs
COLEMAN MARK H
Director · Feb 23
6250 shs
COLEMAN MARK H
Director · Feb 20
12485 shs
COLEMAN MARK H
Director · Feb 10
5193 shs
TABUTEAU HERRIOT
Chief Executive Officer · Feb 02
32410 shs
TABUTEAU HERRIOT
Chief Executive Officer · Feb 02
32410 shs
PIZZIE NICK
Chief Financial Officer · Jan 22
12000 shs
PIZZIE NICK
Chief Financial Officer · Jan 22
12000 shs
Last 90 days
Top Holders
Top 5: 23.62%Vanguard Group Inc
8.14%
$651.2M
Blackrock Inc.
7.65%
$611.9M
Price (T.Rowe) Associates I…
2.95%
$236.1M
Invesco Ltd.
2.49%
$199.1M
Wellington Management Group…
2.39%
$191.0M
As of Dec 31, 2025
Latest News
No related news yet